Showing 2861-2870 of 5685 results for "".
- Takeda, Shire Shareholders to Vote on Merger Deal Next Monthhttps://modernod.com/news/takeda-shire-shareholders-to-vote-on-merger-deal-next-month/2479678/Takeda and Shire announced that shareholders will vote on December 5 on the companies’ proposed $62-billion merger, with the Japanese drugmaker targeting January 8, 2019 for closing of the deal. Takeda CEO Christophe Weber remarked “with the date of our extraordinary general meeting (
- EyePoint Pharmaceuticals Announces Assignment of Permanent J-Code for Dexycu by CMShttps://modernod.com/news/eyepoint-pharmaceuticals-announces-assignment-of-permanent-j-code-for-dexycu-by-the-center-for-medicare-and-medicaid-services-cms/2479679/EyePoint Pharmaceuticals announced that the Centers for Medicare and Medicaid Services (CMS) has assigned a specific and permanent reimbursement J-code through the Healthcare Common Procedure Coding System (HCPCS) for Dexycu (dexamethasone intraocular suspension) 9%. Dexycu is the first and only
- Prospective Study for NaturalVue Multifocal Demonstrates Decreased Refractive Error Change in Fast-Progressing Myopic Childrenhttps://modernod.com/news/prospective-study-for-naturalvue-multifocal-demonstrates-decreased-refractive-error-change-in-fast-progressing-myopic-children/2479681/Thomas Aller, OD, presented updated findings from a prospective clinical trial of NaturalVue (etafilcon A) 1 Day Multifocal Contact Lenses at a briefing for media and industry leaders at the American Academy of Optometry (AAO) Conference in San Antonio on November 9. The NaturalVue portfolio of p
- Study Demonstrates Galimedix Therapeutics’ MRZ-99030 Eye Drops Neutralize the Reproduction of Misfolded Amyloid-Betahttps://modernod.com/news/new-in-vitro-study-demonstrates-galimedix-therapeutics-investigational-compound-mrz-99030-eye-drops-neutralizes-the-reproduction-of-misfolded-amyloid-beta/2479684/Galimedix Therapeutics announced the results of a new study at the Society for Neuroscience conference demonstrating that a single application of the investigational compound MRZ-99030, also known as GAL-101, causes sustained prevention of misfolded amyloid beta molecules from aggregating into to
- Millennial Demographics Drive Refractive Surgery Opportunity in UShttps://modernod.com/news/millennial-demographics-drive-refractive-surgery-opportunity-in-us/2479686/Wealth, health, and education are key factors in determining the opportunity for laser vision correction (LVC) procedures in the US, according to new Market Scope data. Refractive procedures are strongly driven by the country’s millennial population, and the high opportunity population is
- Bausch’s Papa Says ‘Transformation on Track’ as Debt Paydown Continueshttps://modernod.com/news/bauschs-papa-says-transformation-on-track-as-debt-paydown-continues/2479690/The turnaround at Quebec-based Bausch Health Cos. appeared to take another step forward Tuesday, after the company reported positive organic growth for the third quarter, sending shares up more than five percent in Toronto, according to a Financial Post
- Oxurion and Beta Therapeutics To Develop New Heparanase Inhibitors for Treatment of dry AMDhttps://modernod.com/news/oxurion-and-beta-therapeutics-to-develop-new-heparanase-inhibitors-for-treatment-of-dry-amd/2479697/Oxurion announced that it entered into a strategic research collaboration with Beta Therapeutics (Canberra, Australia) to develop new heparanase inhibitors for the treatment of retinal disorders with large unmet medical needs such as dry age-related macular degeneration. Under the terms of
- New Data from Johnson & Johnson Vision Highlights the Need and Potential Standards for Evidence-Based Decision-Making in Myopiahttps://modernod.com/news/new-data-from-johnson-johnson-vision-highlights-the-need-and-potential-standards-for-evidence-based-decision-making-in-myopia/2479698/Johnson & Johnson Vision announced that Noel A Brennan, PhD, the company’s Global Platform Lead for Myopia Control, will present data on myopia progression and investigational methods to control it at the 2018 American Academy of Optometry Annual Meeting, held November 7-10 in San Antonio, Te
- $4 Million Gift to Aid Construction of a Public Museum Dedicated to Vision and Eye Healthhttps://modernod.com/news/aao-announces-4-million-gift-to-aid-construction-of-a-public-museum-dedicated-to-vision-and-eye-health/2479720/The American Academy of Ophthalmology announced a project to construct the world’s first public museum dedicated to vision and eye health. The new museum will be located in San Francisco. Prominent ophthalmologist Stanley M. Truhlsen, MD, launched the project with a $4 million donation. The annou
- Novartis: Two-Year Head-to-Head Data for Brolucizumab Reaffirm Superiority vs Aflibercept in Reducing Retinal Fluid in Patients With Wet AMDhttps://modernod.com/news/novartis-two-year-head-to-head-data-for-brolucizumab-reaffirm-superiority-vs-aflibercept-in-reducing-retinal-fluid-in-patients-with-wet-amd/2479727/Novartis announced additional brolucizumab phase 3 results from year 2 (96 weeks) that reaffirmed its positive year 1 (48 weeks) findings. Brolucizumab met its primary endpoint of noninferiority versus aflibercept in best corrected visual acuity (BCVA) and exhibited superiority in key retinal out